Active	Status	Sponsor type	Region	Phase	Filter
1 Active 11 Inactive 12 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

1 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Eysuvis (loteprednol etabonate nano-suspension 0.25%) / Kala Pharma
NCT05136443: Loteprednol Etabonate 0.25% for Prevention of Cornea Transplant Rejection	Completed	4	70	US	loteprednol etabonate 0.25% ophthalmic suspension, Eysuvis	Price Vision Group, Kala Pharmaceuticals, Inc.	Corneal Endothelial Dystrophy, Corneal Edema	09/23	09/23
KPI-285 / Kala Pharma
No trials found